< O
TO_SEE O
> O
CASE O
SUMMARY O
: O
A O
92-year O
old O
white O
woman O
who O
was O
receiving O
venlafaxine T
for O
management O
of O
depression D
was O
found O
to O
have O
hyponatremia O

Touch O
sensibility O
was O
assessed O
with O
von O
Frey O
's O
monofilaments O
in O
the O
breasts O
of O
10 O
healthy O
women O
( O
controls O
) O
and O
of O
80 O
women O
with O
breast D
cancer D
who O
at O
least O
1 O
year O
previously O
had O
undergone O
subcutaneous T
mastectomy T
and O
immediate O
reconstruction O
with O
a O
prosthesis O

Although O
improved O
glycemic T
control T
, O
maintenance O
of O
normal O
blood O
pressure O
, O
and O
use O
of O
angiotensin-converting T
enzyme T
inhibitors T
are O
important O
strategies O
to O
avoid O
developing O
microalbuminuria D
, O
dietary O
macronutrient O
intake O
may O
also O
play O
a O
role O

Local O
injection O
of O
corticosteroids T
into O
refractory O
esophageal O
strictures O
to O
decrease O
the O
restenosis D
rate O
has O
been O
reported O

We O
systematically O
reviewed O
the O
evidence O
concerning O
the O
ability O
of O
five O
systemic T
treatments T
to O
induce O
remission O
in O
patients O
with O
severe D
psoriasis D
: O
ultraviolet T
B T
( T
UVB T
) T
, O
photochemotherapy T
( T
PUVA T
) T
, O
methotrexate T
( T
MTX T
) T
, O
retinoids T
( T
RET T
) T
and O
cyclosporin T
A T
( T
CYA T
) T

Consequently O
, O
parenteral T
nutrition T
( T
PN T
) T
solutions T
used O
to O
treat O
malnourished O
patients O
with O
chronic D
renal D
failure D
usually O
are O
prepared O
with O
little O
supplementation O
of O
these O
cations O

< O
TO_SEE O
> O
CONCLUSIONS O
: O
Malnourished O
patients O
with O
chronic D
renal D
failure D
receiving O
PN T
are O
at O
risk O
of O
developing O
electrolyte D
abnormalities D
, O
particularly O
hypophosphatemia D

PURPOSE O
: O
We O
report O
a O
multicenter O
experience O
using O
tubularized T
incised T
plate T
urethroplastym T
for O
proximal D
hypospadias D

MATERIALS O
AND O
METHODS O
: O
From O
August O
1993 O
to O
December O
1996 O
tubularized T
incised T
plate T
urethroplasty T
was O
performed O
in O
27 O
boys O
6 O
months O
to O
3 O
years O
old O
with O
mid D
shaft D
and D
penoscrotal D
hypospadias D

RESULTS O
: O
Tubularized T
incised T
plate T
surgery T
created O
a O
functional O
neourethra O
even O
in O
penoscrotal D
hypospadias D

CONCLUSIONS O
: O
Tubularized T
incised T
plate T
urethroplasty T
is O
a O
versatile O
operation O
that O
corrects O
proximal D
hypospadias D
defects D
with O
few O
complications O
and O
superior O
cosmetic O
results O

Aortocoronary T
bypass T
grafting T
is O
an O
accepted O
procedure O
for O
ischemic D
heart D
disease D

Immunotherapy T
of O
mice O
with O
preexisting O
cancers D
with O
heat T
shock T
protein T
preparations T
derived T
from T
autologous T
cancer T
resulted O
in O
retarded O
progression O
of O
the O
primary O
cancer D
, O
a O
reduced O
metastatic O
load O
, O
and O
prolongation O
of O
life-span O

< O
TO_SEE O
> O
Intrapleural T
injection T
of T
irradiated T
LLC-IL2 T
cured O
pre-existing D
lung D
LLC D
tumors D
and O
extended O
the O
survival O
of O
the O
mice O
but O
did O
not O
affect O
survival O
of O
mice O
with O
pre-existing O
peritoneal D
tumors D
nor O
did O
it O
affect O
the O
growth O
of O
s.c. D
tumors D

< O
TO_SEE O
> O
Intraperitoneal T
injection T
of T
irradiated T
LLC-IL2 T
cured O
pre-existing D
LLC D
peritoneal D
tumors D
and O
extended O
the O
survival O
of O
the O
mice O
but O
did O
not O
affect O
survival O
of O
mice O
bearing O
lung D
tumors D
nor O
did O
it O
affect O
the O
growth O
of O
s.c. D
tumors D

Subcutaneous T
injection T
of T
irradiated T
LLC-IL2 T
did O
not O
affect O
the O
growth O
of O
preexisting O
s.c. D
tumors D
and O
also O
did O
not O
improve O
survival O
of O
mice O
bearing O
the O
lung D
or D
peritoneal D
tumors D

We O
describe O
such O
an O
event O
in O
a O
man O
who O
underwent O
allogeneic T
BMT T
for O
APL D
in O
second O
relapse O
and O
4 O
years O
later O
presented O
with O
testicular O
relapse O

Olanzapine T
is O
an O
atypical O
antipsychotic O
effective O
in O
the O
treatment O
of O
schizophrenic D
patients D

After O
a O
2- O
to O
9-day O
placebo O
lead-in O
, O
79 O
inpatients O
with O
schizophrenia D
according O
to O
DSM-III-R O
criteria O
were O
placed O
on O
an O
olanzapine T
dosage O
of O
10 O
mg/day O
or O
1 O
mg/day O
for O
up O
to O
6 O
weeks O

Fludarabine T
and O
ara-C T
successfully O
eradicated O
bone D
marrow D
disease D
in O
16 O
of O
27 O
patients O
( O
59 O
% O
) O
, O
23 O
patients O
of O
which O
had O
been O
treated O
previously O
with O
high-dose O
ara-C T

These O
results O
verified O
the O
synergistic O
effect O
fludarabine T
exhibited O
in O
augmenting O
ara-CTP T
concentrations O
in O
patients O
' O
leukemic O
blasts O
, O
thus O
improving O
the O
clinical O
response O
in O
relapsed D
pediatric D
leukemias D

BACKGROUND O
: O
The O
growing O
use O
of O
heparin T
in O
acute D
thrombotic D
disorders D
, O
coupled O
with O
the O
availability O
of O
many O
new O
antithrombotic T
agents T
, O
emphasizes O
the O
need O
for O
adequate O
characterization O
of O
the O
platelet O
effects O
of O
the O
various O
anticoagulants T

METHODS O
AND O
RESULTS O
: O
Platelet O
P-selectin O
( O
CD62 O
) O
and O
activated O
GP O
IIb/IIIa O
( O
PAC-1 O
) O
expression O
on O
platelet O
membrane O
was O
quantified O
in O
whole O
blood O
as O
well O
as O
platelet O
aggregation O
in O
platelet-rich O
plasma O
in O
43 O
patients O
with O
unstable D
angina D
before O
and O
during O
treatment O
with O
UFH T
or O
enoxaparin T

PURPOSE O
: O
We O
review O
our O
initial O
experience O
with O
direct T
percutaneous T
transluminal T
angioplasty T
( T
PTA T
) T
as O
a O
reperfusion T
treatment T
for O
acute D
occlusion D
of D
the D
middle D
cerebral D
artery D

< O
TO_SEE O
> O
CONCLUSION O
: O
Direct O
PTA O
may O
be O
performed O
safely O
as O
an O
alternative O
to O
thrombolytic O
therapy O
in O
patients O
with O
acute O
occlusion O
of O
the O
middle O
cerebral O
artery O
when O
early O
CT O
findings O
and/or O
lenticulostriate O
artery O
involvement O
are O
present O
or O
when O
superselective O
local O
angiography O
shows O
the O
presence O
of O
a O
large O
embolus O
or O
high-grade O
stenosis O

Women O
randomised O
to O
screen-and-treat O
received O
appropriate O
antibiotics T
only O
if O
screening O
proved O
positive O
for O
one O
or O
more O
infection D

< O
TO_SEE O
> O
A O
71-year-old O
woman O
with O
autoimmune O
hemolytic O
anemia O
underwent O
an O
emergency O
endocardial T
patch T
repair T
for O
ventricular D
septal D
perforation D
after O
acute O
myocardial O
infarction O

Use O
of O
washed T
red T
blood T
cells T
was O
effective O
in O
averting O
hemolytic D
crisis D
throughout O
perioperative O
period O

Therefore O
, O
prudent O
management O
and O
use O
of O
washed T
red T
blood T
cells T
transfusion T
would O
prevent O
hemolytic D
aggravation D
even O
in O
open O
heart O
surgery O

< O
TO_SEE O
> O
We O
report O
a O
case O
of O
a O
29-year-old O
male O
chronic O
HBV O
carrier O
who O
developed O
fulminant D
reactivated D
HBV D
infection D
following O
intensive O
chemotherapy T
for O
stage D
IVB D
large D
cell D
B-cell D
non-Hodgkin D
's D
lymphoma D
associated O
with O
extensive O
central O
nervous O
system O
and O
bone O
marrow O
involvement O

We O
advise O
that O
lamivudine T
should O
be O
considered O
during O
intensive O
chemotherapy T
treatment T
of O
chronic O
carriers O
of O
HBV D

OBJECTIVES O
: O
The O
purpose O
of O
this O
analysis O
was O
to O
determine O
the O
influence O
of O
an O
additional O
treatment O
delay O
inherent O
in O
transfer O
to O
an O
angioplasty O
center O
for O
primary T
angioplasty T
of O
patients O
with O
acute D
myocardial D
infarction D
who O
are O
first O
admitted O
to O
hospitals O
without O
angioplasty O
facilities O

BACKGROUND O
: O
Several O
randomized O
trials O
have O
demonstrated O
the O
benefits O
of O
primary T
angioplasty T
in O
acute D
myocardial D
infarction D

We O
report O
the O
first O
case O
( O
to O
our O
knowledge O
) O
of O
an O
endoscopic T
removal T
of O
a O
forehead D
soft D
tissue D
mass D

As O
the O
overview O
shows O
, O
both O
groups O
of O
substances O
are O
useful O
for O
individualized O
treatment O
of O
benign D
prostatic D
hyperplasia D
( D
BPH D
) D
, O
provided O
that O
conservative O
pharmacological T
treatment T
of O
BPH D
is O
basically O
accepted O
and O
that O
the O
patients O
' O
quality O
of O
life O
is O
also O
considered O

The O
results O
of O
several O
clinical O
investigations O
showed O
the O
efficacy O
and O
safety O
of O
artichoke T
extracts T
( T
Cynara T
scolymus T
L. T
) T
in O
the O
treatment O
of O
hepato-biliary D
dysfunction D
and D
digestive D
complaints D
, O
such O
as O
sensation O
of O
fullness O
, O
loss D
of D
appetite D
, O
nausea D
and O
abdominal D
pain D

Besides O
the O
well-known O
nonsteroidal T
antiinflammatory T
drugs T
( T
NSAID T
) T
for O
the O
treatment O
of O
rheumatic D
pain D
herbal T
medicine T
can O
also O
be O
applied O
successfully O

Extracts O
of O
the O
secondary O
tubers O
of O
Devil T
's T
Claw T
( T
Harpagophytum T
procumbens T
) T
are O
recommended O
for O
the O
supportive O
treatment O
of O
degenerative D
painful D
rheumatism D

High-dose T
intravenous T
immunoglobulin T
( T
hdIVIg T
) T
is O
increasingly O
used O
to O
treat O
a O
range O
of O
inflammatory D
and D
autoimmune D
diseases D

The O
current O
dermatological O
uses O
of O
hdIVIg T
include O
the O
treatment O
of O
dermatomyositis D
and O
the O
autoimmune D
bullous D
disorders D
, O
epidermolysis D
bullosa D
acquisita D
, O
pemphigoid D
, O
and O
pemphigus D

Unfortunately O
, O
current O
dermatological O
uses O
of O
hdIVIg O
have O
been O
limited O
to O
either O
uncontrolled O
trials O
or O
anecdotal O
case O
reports O
, O
except O
for O
a O
single O
controlled O
trial O
of O
hdIVIg T
as O
adjunctive O
therapy O
in O
patients O
with O
dermatomyositis D
, O
which O
documented O
a O
significant O
benefit O

We O
describe O
a O
technique O
that O
enables O
the O
autologous T
repair T
of O
large D
midline D
incisional D
hernias D
by O
restoring O
the O
functional O
musculoaponeurotic O
support O
of O
the O
abdominal O
wall O

OBJECTIVE O
AND O
IMPORTANCE O
: O
The O
use O
of O
chronic T
intrathecal T
morphine T
for O
the O
treatment O
of O
intractable D
, D
nonmalignant D
pain D
is O
becoming O
more O
prevalent O

METHODS O
: O
During O
a O
19-month O
period O
, O
seven O
children O
with O
empyema D
underwent O
thoracoscopy T

< O
TO_SEE O
> O
We O
describe O
a O
patient O
with O
left D
cardiac D
herniation D
presenting O
after O
intrapericardial T
pulmonectomy T
for O
primary D
lung D
cancer D

The O
growing O
use O
of O
automated T
night-time T
dialysis T
( T
APD T
) T
in O
peritoneal D
dialysis D
over O
the O
last O
few O
years O
shows O
that O
this O
method O
represents O
a O
valid O
alternative O
to O
continuous T
ambulatory T
peritoneal T
dialysis T
( T
CAPD T
) T

La O
Serna O
et O
al O
. O
( O
Lancet O
1987 O
; O
26 O
: O
1517 O
) O
were O
the O
first O
to O
treat O
adults O
with O
recurrent D
pericarditis D
with O
colchicine T
, O
and O
were O
followed O
by O
other O
authors O

While O
these O
findings O
are O
observed O
for O
all O
classes O
of O
oral O
drugs O
, O
the O
issue O
is O
especially O
critical O
for O
cancer D
chemotherapy T
, O
in O
which O
a O
narrow O
therapeutic O
index O
is O
frequently O
observed O

Treatment O
for O
low-grade D
NHL D
during O
the O
past O
30 O
yr O
has O
consisted O
of O
high-dose T
radiation T
and O
cytotoxic T
agents T
, O
administered O
alone O
or O
in O
combination O
, O
and O
high-dose T
therapy T
with T
stem T
cell T
transplant T

However O
, O
recent O
clinical O
use O
of O
monoclonal T
antibodies T
( T
mAbs T
) T
in O
patients O
with O
low-grade D
or D
transformed D
low-grade D
NHL D
has O
resulted O
in O
less O
toxicity O
than O
conventional O
treatments O
, O
as O
well O
as O
response O
rates O
that O
are O
comparable O
or O
superior O
to O
those O
achieved O
with O
chemotherapy T

Therefore O
, O
interest O
is O
growing O
in O
mAbs T
as O
therapeutic O
alternatives O
for O
patients O
with O
low-grade D
NHL D
and O
those O
with O
transformed O
histology O

CONCLUSION O
: O
The O
treatment O
paradigm O
for O
NHL D
is O
expected O
to O
change O
over O
the O
next O
few O
years O
to O
include O
radiolabeled T
mAbs T
, O
administered O
alone O
or O
in O
combination O
with O
cytotoxic T
agents T

RESULTS O
: O
Clinical O
trials O
of O
UFT T
published O
in O
the O
Western O
world O
have O
included O
581 O
patients O
with O
colorectal D
cancer D

The O
activity O
of O
oral T
UFT T
in O
large-bowel D
cancer D
when O
administered O
with O
oral T
LV T
( O
approximately O
50 O
mg/dose O
) O
has O
resulted O
in O
objective O
response O
rates O
of O
approximately O
40 O
% O

CONCLUSION O
: O
UFT T
is O
a O
fluoropyrimidine T
active O
in O
colorectal D
cancer D

BACKGROUND O
: O
Adrenalectomy T
is O
the O
current O
treatment O
for O
phaeochromocytoma D

CONCLUSION O
: O
Adrenal-sparing T
surgery T
is O
safe O
and O
effective O
, O
and O
may O
become O
the O
treatment O
of O
choice O
in O
patients O
with O
hereditary D
phaeochromocytoma D

< O
TO_SEE O
> O
PURPOSE O
: O
The O
purposes O
of O
this O
descriptive O
, O
longitudinal O
study O
were O
to O
evaluate O
the O
MacDibbs O
Mouth O
Assessment O
instrument O
for O
the O
assessment O
of O
mucositis O
in O
the O
radiation T
therapy T
patient O
being O
treated O
for O
head D
and D
neck D
cancer D
and O
to O
describe O
the O
course O
of O
radiation-induced D
mucositis D
in O
these O
patients O

< O
TO_SEE O
> O
As O
concomitant D
thrombocytosis D
persisted O
despite O
treatment O
with O
hydroxyurea T
, O
the O
new O
megakaryocyte T
inhibitor T
anagrelide T
( T
Agrelin T
) T
was O
administered O
and O
led O
to O
normalization O
of O
the O
platelet O
count O
within O
11 O
days O

Background O
: O
Troglitazone T
is O
a O
new O
drug O
for O
the O
treatment O
of O
type D
2 D
diabetes D

< O
TO_SEE O
> O
For O
a O
subset O
of O
patients O
with O
Kaposi D
's D
sarcoma D
who O
were O
treated O
with O
recombinant T
interferon T
alfa-2a T
, O
the O
disease O
is O
in O
complete O
remission O
, O
without O
opportunistic D
infection D
, O
and O
they O
appear O
to O
be O
culture-negative O
for O
the O
etiologic O
retrovirus O
that O
causes O
their O
immune D
deficiency D

Interferon T
alfa-2a T
appears O
to O
have O
antineoplastic O
efficacy O
, O
( O
and O
may O
have O
antiretroviral O
efficacy O
as O
well O
) O
in O
this O
epidemic O
neoplasm D

In O
three O
consecutive O
Phase O
II O
trials O
of O
recombinant T
interferon T
alfa-2a T
( O
rIFN O
alfa-2a O
; O
Roferon-A O
Hoffmann-La O
Roche O
, O
Nutley O
, O
NJ O
) O
involving O
96 O
patients O
with O
advanced D
malignant D
melanoma D
, O
an O
overall O
response O
rate O
of O
22 O
% O
was O
observed O

As O
single O
agent O
therapy O
in O
malignant D
melanoma D
, O
interferon T
alfa-2a T
was O
only O
marginally O
useful O
in O
most O
patients O

Studies O
with O
various O
interferon T
alpha T
preparations T
, O
including O
interferons T
induced O
in O
human O
leukocytes O
, O
interferon T
alfa-N1 T
, O
interferon T
alfa-2a T
, O
and O
interferon T
alfa-2b T
, O
have O
all O
provided O
evidence O
for O
modest O
but O
reproducible O
antitumor O
activity O
in O
advanced D
renal D
cell D
carcinoma D

Preliminary O
evidence O
suggests O
that O
interferons T
beta T
and T
gamma T
may O
also O
induce O
regression O
of O
metastatic D
renal D
cell D
carcinoma D

The O
rationale O
for O
antileukemic T
therapy T
in O
hairy D
cell D
leukemia D
is O
to O
reduce O
the O
significant O
risk O
of O
infection O
and O
other O
potential O
serious O
complications O

Splenectomy T
presumably O
alleviates O
the O
pancytopenic O
effect O
of O
hypersplenism D
by O
removing O
the O
preferred O
site O
of O
leukemic O
cell O
proliferation O

Recombinant O
and O
natural O
forms O
of O
interferon T
alpha T
have O
been O
shown O
to O
bring O
about O
tumor O
regressions O
in O
patients O
with O
low-grade D
non-Hodgkin D
's D
lymphoma D

Current O
studies O
using O
interferon T
in O
patients O
with O
low-grade D
non-Hodgkin D
's D
lymphomas D
are O
evaluating O
lower O
, O
and O
perhaps O
better O
tolerated O
doses O
of O
interferon T

This O
approach O
is O
being O
extended O
to O
the O
clinic O
, O
and O
trials O
are O
now O
underway O
evaluating O
combinations O
of O
interferon T
and O
various O
cytotoxic T
drugs T
known O
from O
previous O
studies O
to O
be O
active O
in O
patients O
with O
low-grade D
non-Hodgkin D
's D
lymphomas D

While O
the O
demonstrated O
antiviral O
, O
antiproliferative O
, O
and O
immunomodulatory O
properties O
of O
interferons T
have O
led O
to O
a O
number O
of O
theories O
regarding O
their O
potential O
use O
in O
treating O
individuals O
with O
chronic D
myelogenous D
leukemia D
( D
CML D
) D
, O
their O
limited O
availability O
has O
prevented O
thorough O
clinical O
investigation O

The O
data O
resulting O
from O
these O
clinical O
trials O
indicate O
that O
interferon T
alfa-2a T
is O
effective O
in O
inducing O
hematologic O
remissions O
in O
the O
majority O
of O
minimally O
treated O
, O
benign-phase D
CML D
, O
Ph1-positive O
patients O

More O
than O
1600 O
patients O
with O
neoplastic D
disorders D
have O
received O
recombinant T
human T
interferon T
alfa-2a T
( T
Roferon-A T
, T
Hoffmann-La T
Roche T
, T
Nutley T
, T
NJ T
) T
as O
part O
of O
ongoing O
or O
completed O
clinical O
trials O

PURPOSE O
: O
A O
phase O
I/II O
trial O
of O
docetaxel T
, O
cisplatin T
, O
fluorouracil T
( T
5-FU T
) T
, O
and O
leucovorin T
( T
TPFL5 T
) T
induction T
chemotherapy T
for O
patients O
with O
locally D
advanced D
squamous D
cell D
carcinoma D
of D
the D
head D
and D
neck D
( D
SCCHN D
) D

PATIENTS O
AND O
METHODS O
: O
Twenty-three O
previously O
untreated O
patients O
with O
stage D
III D
or D
IV D
SCCHN D
and O
Eastern O
Cooperative O
Oncology O
Group O
functional O
status O
less O
than O
or O
equal O
to O
2 O
were O
treated O
with O
TPFL5 T

Intrathecal T
sufentanil T
provides O
approximately O
2 O
h O
of O
excellent O
labor D
analgesia O
with O
minimal O
motor O
blockade O

OBJECTIVE O
: O
We O
report O
the O
results O
of O
a O
double-blind O
, O
double-dummy O
, O
active-control O
study O
designed O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
lamotrigine T
( T
LTG T
) T
administered O
as O
monotherapy O
to O
adult O
outpatients O
with O
partial D
seizures D

BACKGROUND O
: O
The O
effectiveness O
of O
LTG T
as O
add-on O
therapy O
for O
partial D
seizures D
in O
adults O
has O
previously O
been O
established O

CONCLUSIONS O
: O
We O
conclude O
that O
LTG T
is O
effective O
and O
well O
tolerated O
when O
administered O
as O
monotherapy O
in O
adult O
patients O
with O
partial D
seizures D

BACKGROUND O
: O
Omega3 O
fatty O
acids O
may O
inhibit O
neuronal O
signal O
transduction O
pathways O
in O
a O
manner O
similar O
to O
that O
of O
lithium T
carbonate T
and O
valproate T
, O
2 O
effective O
treatments O
for O
bipolar D
disorder D

The O
present O
study O
was O
performed O
to O
examine O
whether O
omega3 T
fatty T
acids T
also O
exhibit O
mood-stabilizing O
properties O
in O
bipolar D
disorder D

CONCLUSION O
: O
Omega3 T
fatty T
acids T
were O
well O
tolerated O
and O
improved O
the O
short-term O
course O
of O
illness O
in O
this O
preliminary O
study O
of O
patients O
with O
bipolar D
disorder D

Several O
large-scale O
trials O
have O
firmly O
established O
the O
effectiveness O
of O
thrombolytic T
therapy T
, O
beta T
blockers T
, O
and O
aspirin T
in O
the O
treatment O
of O
AMI D

< O
TO_SEE O
> O
While O
diastolic D
left D
ventricular D
( D
LV D
) D
dysfunction D
is O
frequent O
and O
associated O
with O
cardiovascular D
complications D
in O
end-stage D
renal D
disease D
treated O
with O
dialysis T
, O
controversial O
information O
exists O
on O
diastolic O
LV O
function O
after O
renal O
transplantation O

METHODS O
: O
Fluvastatin T
40 O
mg O
daily O
was O
administered O
to O
25 O
patients O
with O
hypercholesterolaemia D
for O
up O
to O
24 O
weeks O

The O
inhibitory O
effect O
of O
n-3 T
polyunsaturated T
fatty T
acids T
on O
human D
colorectal D
cancer D
has O
been O
speculated O
on O
from O
epidemiological O
data O
and O
animal O
studies O

We O
conducted O
a O
long-term O
trial O
of O
docosahexanoic T
acid T
( T
DHA T
) T
-concentrated T
fish T
oil T
capsules T
for O
patients O
in O
a O
high-risk O
group O
for O
colorectal D
cancer D

Three O
patients O
with O
FAP D
and O
two O
patients O
with O
multiple O
( O
more O
than O
30 O
) O
colorectal D
polyps D
were O
administered O
DHA-concentrated T
fish T
oil T
capsules_Hlk427554600 T
( T
2.2 T
g T
of T
DHA T
and T
0.6 T
g T
of T
eicosapentanoic T
acid T
( T
EPA T
) T
per T
day T
) T
for O
one O
or O
two O
years O

This O
article O
reviews O
current O
trends O
in O
management O
of O
esophageal D
achalasia D
, O
highlighting O
short-term O
outcome O
and O
cost O
comparisons O
of O
three O
treatments O
: O
botulinum T
toxin T
injection T
, O
pneumatic T
dilation T
, O
and O
laparoscopic T
myotomy T

The O
clinical O
application O
of O
therapeutic T
hysteroscopy T
, O
mainly O
in O
the O
field O
of O
the O
treatment O
of O
abnormal D
uterine D
bleeding D
, O
started O
in O
the O
1980s O

< O
TO_SEE O
> O
In O
this O
article O
, O
evidence O
of O
effectiveness O
and O
cost-effectiveness O
of O
the O
following O
procedures O
is O
reviewed O
: O
( O
1 O
) O
laser T
treatment T
of O
bladder D
tumors D
; O
( O
2 O
) O
extracorporeal O
shock-wave O
lithotripsy O
and O
percutaneous O
nephrolithotomy O
; O
( O
3 O
) O
laparoscopic T
treatment T
of O
endometriosis D
; O
( O
4 O
) O
laparoscopic T
removal T
of O
ovarian D
cysts D
; O
( O
5 O
) O
laparoscopic O
cholecystectomy O
; O
( O
6 O
) O
laparoscopic O
appendectomy O
; O
( O
7 O
) O
catheter T
treatment T
of O
coronary D
artery D
disease D
; O
( O
8 O
) O
palliation O
of O
colon O
cancer O
by O
endoscopic O
intervention O
; O
( O
9 O
) O
treatment O
of O
upper D
gastrointestinal D
( D
UGI D
) D
bleeding D
by O
endoscopic T
intervention T
; O
and O
( O
10 O
) O
arthroscopic O
knee O
surgery O

Gene T
therapy T
of O
malignant D
brain D
tumors D

Treatment O
of O
irritable D
bowel D
syndrome D
with O
Chinese T
herbal T
medicine T
: O
a O
randomized O
controlled O
trial O

Randomised O
trial O
of O
interferon T
alpha2b T
plus T
ribavirin T
for O
48 O
weeks O
or O
for O
24 O
weeks O
versus O
interferon T
alpha2b T
plus T
placebo T
for O
48 O
weeks O
for O
treatment O
of O
chronic D
infection D
with D
hepatitis D
C D
virus D

Low-molecular-weight T
heparin T
for O
immediate O
management O
of O
thromboembolic D
disease D
in O
pregnancy O

Tubularized T
incised T
plate T
hypospadias T
repair T
for O
proximal D
hypospadias D

Comparison O
of O
radical T
prostatectomy T
and O
iodine T
125 T
interstitial T
radiotherapy T
for O
the O
treatment O
of O
clinically D
localized D
prostate D
cancer D
: O
a O
7-year O
biochemical O
( O
PSA O
) O
progression O
analysis O

The O
effectiveness O
of O
acupuncture T
in O
treating O
acute D
dental D
pain D
: O
a O
systematic O
review O

Correction O
of O
cardiac D
defects D
through O
a O
right T
thoracotomy T
in O
children O

New O
technique O
for O
mesh T
repair T
of O
paracolostomy D
hernias D

Immunotherapy T
of O
tumors D
with O
autologous T
tumor-derived T
heat T
shock T
protein T
preparations T

Comprehensive T
modified T
diet T
simplifies O
nutrition T
management T
of O
adults O
with O
short-bowel D
syndrome D

Extended O
use O
of O
glatiramer T
acetate T
( T
Copaxone T
) T
is O
well O
tolerated O
and O
maintains O
its O
clinical O
effect O
on O
multiple D
sclerosis D
relapse O
rate O
and O
degree O
of O
disability O

European O
register O
of O
patients O
with O
sickle D
cell D
disease D
treated O
with O
hydroxyurea T
is O
being O
set O
up O

Understanding O
the O
culture O
of O
prescribing O
: O
qualitative O
study O
of O
general O
practitioners O
' O
and O
patients O
' O
perceptions O
of O
antibiotics T
for O
sore D
throats D

Steroid T
delivery T
in O
croup D

Haematoma T
block T
versus O
intravenous T
regional T
anaesthesia T
in O
Colles D
' D
fractures D

Direct T
percutaneous T
transluminal T
angioplasty T
for O
acute D
middle D
cerebral D
artery D
occlusion D

Magnesium T
sulphate T
for O
the O
control O
of O
spasms D
in D
severe D
tetanus D

Protective O
effect O
of O
pralidoxime T
on O
muscle D
fiber D
necrosis D
induced O
by O
organophosphate O
compounds O

Assessment O
of O
atrioventricular T
junction T
ablation T
and T
VVIR T
pacemaker T
versus O
pharmacological T
treatment T
in O
patients O
with O
heart D
failure D
and D
chronic D
atrial D
fibrillation D
: O
a O
randomized O
, O
controlled O
study O

Statins T
for O
prevention O
of O
stroke D

Repair O
of O
ventral D
hernias D
with O
expanded T
polytetrafluoroethylene T
patch T

Spinal T
manipulation T
in O
the O
treatment O
of O
episodic D
tension-type D
headache D
: O
a O
randomized O
controlled O
trial O

Successful O
treatment O
with O
lamivudine T
for O
fulminant D
reactivated D
hepatitis D
B D
infectioN D
following O
intensive T
therapy T
for O
high-grade D
non-Hodgkin D
's D
lymphoma D

Influence O
of O
treatment O
delay O
on O
infarct O
size O
and O
clinical O
outcome O
in O
patients O
with O
acute D
myocardial D
infarction D
treated O
with O
primary T
angioplasty T

Should O
patients O
with O
advanced D
sarcomas D
be O
treated O
with O
chemotherapy T
? O

Plasma T
exchange T
and T
tacrolimus-mycophenolate T
rescue T
for O
acute D
humoral D
rejection D
in O
kidney O
transplantation O

Hyperbaric T
oxygen T
therapy T
for O
children O
with O
cerebral D
palsy D

Endoscopic T
excision T
of O
a D
forehead D
mass D

Effect O
of O
photodynamic T
therapy T
in T
combination T
with T
mitomycin T
C T
on O
a O
mitomycin-resistant D
bladder D
cancer D
cell O
line O

Is O
conservative T
surgery T
for O
tubal D
pregnancy D
preferable O
to O
salpingectomy T
? O
An O
economic O
analysis O

Laparoscopic T
cornuostomy T
in O
the O
treatment O
of O
interstitial D
pregnancy D
with O
subsequent O
hysterosalpingography O

Experimental O
evaluation O
of O
the O
use O
of O
recombinant T
prourokinase T
and O
its O
immobilized O
forms O
in O
the O
treatment O
of O
postoperative D
fibrinoid D
syndrome D
in O
ophthalmology O

In O
vitro O
and O
in O
vivo O
comparison O
between O
the O
effects O
of O
treatment O
with O
adenosine T
triphosphate T
and O
treatment O
with O
buthionine T
sulfoximine T
on O
chemosensitization O
and O
tumour O
growth O
of O
B16 D
melanoma D

Effects O
of O
transpupillary T
thermotherapy T
on O
immunological O
parameters O
and O
apoptosis O
in O
a O
case O
of O
primary D
uveal D
melanoma D

Is O
there O
a O
rational O
therapy O
for O
symptomatic O
treatment O
of O
benign D
prostatic D
hyperplasia D
with O
phytogenic T
drugs T
? O
Illustrated O
with O
the O
example O
of O
the O
prostate O
agent O
from O
Serenoa O
repens O
( O
Sabal O
fructus O
) O

Pharmacological O
and O
clinical O
effectiveness O
of O
a O
fixed T
phytogenic T
combination T
trembling T
poplar T
( T
Populus T
tremula T
) T
, T
true T
goldenrod T
( T
Solidago T
virgaurea T
) T
and T
ash T
( T
Fraxinus T
excelsior T
) T
in O
mild D
to D
moderate D
rheumatic D
complaints D

Therapy O
of O
degenerative D
diseases D
of D
the D
musculoskeletal D
system D
with O
South T
African T
devil T
's T
claw T
( T
Harpagophytum T
procumbens T
DC T
) T

Treatment O
strategy O
for O
mucin-producing D
intrahepatic D
cholangiocarcinoma D
: O
value O
of O
percutaneous T
transhepatic T
biliary T
drainage T
and O
cholangioscopy T

Strategy O
for O
surgical T
management T
of O
ileocolonic D
anastomotic D
recurrence D
in D
Crohn D
's D
disease D

Nerve-sparing T
surgery T
for O
advanced D
rectal D
cancer D
patients O
: O
special O
reference O
to O
Dukes O
C O
patients O

Prognostic O
factors O
in O
patients O
with O
locally O
advanced O
rectal D
adenocarcinoma D
treated O
with O
preoperative T
radiotherapy T
and O
surgery T

Current O
surgical T
therapy T
for O
bronchiectasis D

Thoracic T
surgery T
for O
hydatid D
disease D

Surgical T
treatment T
of O
postpneumonic D
empyema D

Thoracoscopic T
surgery T
for O
pulmonary D
tuberculosis D

Thoracoscopic T
surgery T
for O
spontaneous D
pneumothorax D

Surgery T
for O
chronic D
thromboembolic D
pulmonary D
hypertension D

Transabdominal T
extensive T
esophagogastric T
devascularization T
with T
gastroesophageal T
stapling T
for O
management O
of O
noncirrhotic D
portal D
hypertension D
: O
long-term O
results O

Surgical T
treatment T
for O
lung D
hydatid D
disease D

Sliding T
door T
technique T
for O
the O
repair O
of O
midline D
incisional D
hernias D

One-lung T
ventilation T
in O
patients O
with O
difficult D
airways D

Thoracoscopy T
for O
empyema D
in O
children O

Sex O
differences O
in O
the O
use O
of O
asthma D
drugs T
: O
cross O
sectional O
study O

Conventional T
treatments T
for O
non-Hodgkin D
's D
lymphoma D
: O
the O
need O
for O
new O
therapies O

Adrenal-sparing T
surgery T
for O
phaeochromocytoma D

Antiplatelet T
therapy T
in O
acute D
cerebral D
ischemia D

Laugier-Hunziker D
syndrome D
: O
case O
report O
and O
treatment O
with O
the O
Q-switched T
Nd-Yag T
laser T

Thoracoscopic T
operation T
for O
secondary D
pneumothorax D
under O
local O
and O
epidural O
anesthesia O
in O
high-risk O
patients O

Troglitazone-induced D
hepatic D
failure D
leading O
to O
liver T
transplantation T

A O
modified O
technique O
of O
tubeless O
anaesthesia O
for O
microlaryngoscopy T
and T
bronchoscopy T
in O
young O
children O
with O
stridor D

A O
randomized O
trial O
of O
Lactobacillus T
acidophilus T
BG2FO4 T
to O
treat O
lactose D
intolerance D

Treatment O
of O
idiopathic D
thrombopenic D
purpura D
in O
adolescents O
by O
intravenous T
immunoglobulin T

Azithromycin T
therapy T
for O
scrub D
typhus D
during O
pregnancy O

Excimer T
laser T
assisted T
in T
situ T
keratomileusis T
for O
hyperopia D

Three O
consecutive O
phase O
II O
studies O
of O
recombinant T
interferon T
alfa-2a T
in O
advanced D
malignant D
melanoma D

Interferon T
treatment T
of O
renal D
cell D
carcinoma D

Current O
and O
future O
uses O
of O
recombinant T
interferon T
alpha T
in O
the O
treatment O
of O
low-grade D
non-Hodgkin D
's D
lymphoma D

Antimicrobial T
treatment T
options O
in O
the O
management O
of O
odontogenic D
infections D

Recombinant T
glycoprotein T
vaccine T
for O
the O
prevention O
of O
genital D
HSV-2 D
infection D
: O
two O
randomized O
controlled O
trials O

Induction T
chemotherapy T
with T
docetaxel T
, T
cisplatin T
, T
fluorouracil T
, T
and T
leucovorin T
for O
squamous D
cell D
carcinoma D
of O
the O
head O
and O
neck O
: O
a O
phase O
I/II O
trial O

Low-dose T
steroids T
reduce O
flu-like D
symptoms D
at O
the O
initiation O
of O
IFNbeta-1b O
in O
relapsing-remitting O
MS O

Study O
of O
three O
different O
doses O
of O
epidural T
neostigmine T
coadministered T
with T
lidocaine T
for O
postoperative D
analgesia D

An O
active-control O
trial O
of O
lamotrigine T
monotherapy T
for O
partial D
seizures D

< O
TO_SEE O
> O
Safety O
of O
intrathecal T
sodium T
nitroprusside T
for O
the O
treatment O
and O
prevention O
of O
refractory D
cerebral D
vasospasm D
and D
ischemia D
in O
humans O

The O
effect O
of O
heliox T
in O
acute D
severe D
asthma D
: O
a O
randomized O
controlled O
trial O
. O

Long-term O
survival O
of O
patients O
with O
unresectable D
colorectal D
cancer D
liver D
metastases D
following O
infusional T
chemotherapy T
with T
5-fluorouracil T
, T
leucovorin T
, T
oxaliplatin T
and T
surgery T

< O
TO_SEE O
> O
Fatal D
acute D
haemolysis D
in O
an O
AIDS D
patient O
treated O
with O
lindinavir T

A O
simplified O
laparoscopic T
technique T
for T
mesh T
placement T
in O
ventral D
hernia D
repair O

Pharmacological T
management T
of O
acute D
myocardial D
infarction D

Mesenteric D
venous D
thrombosis D
: O
successful O
treatment O
by O
intraarterial T
lytic T
therapy T

Gene T
therapy T
for O
myocardial D
angiogenesis D

Dipyridamole T
plus T
aspirin T
in O
cerebrovascular D
disease D

What O
is O
the O
real O
role O
of O
CD40 O
in O
cancer D
immunotherapy T
? O

The O
effects O
of O
oral T
liarozole T
on O
epidermal O
proliferation O
and O
differentiation O
in O
severe D
plaque D
psoriasis D
are O
comparable O
with O
those O
of O
acitretin T
. O

Safety O
and O
potential O
effectiveness O
of O
daunorubicin-containing T
liposomes T
in O
patients O
with O
advanced D
recurrent D
malignant D
CNS D
tumors D

An O
experimental O
application O
of O
gene T
therapy T
for O
human D
retinoblastoma D

Acid T
suppression T
therapy T
in O
Barrett D
's D
esophagus D
: O
the O
importance O
of O
pH O
monitoring O

Surgical T
approaches T
to O
pediatric D
defecatory D
disorders D

Lutein T
improves O
visual O
function O
in O
some O
patients O
with O
retinal D
degeneration D
: O
a O
pilot O
study O
via O
the O
Internet O

Drug O
information O
questions O
and O
answers O
: O
new O
for O
psoriasis D
: O
colchicine T

IPPB T
in O
severe D
pulmonary D
emphysema D
: O
limited O
applications O

Long-term O
mortality O
in O
patients O
after O
a O
British O
trial O
of O
anticoagulants T
in O
acute D
myocardial D
infarction D

Our O
results O
in O
the O
surgical T
treatment T
of O
habitual D
shoulder D
dislocation D
with O
special O
reference O
to O
occupational O
disability O

Alkaline O
phosphatase O
in O
neutrophil O
leukocytes O
of O
patients O
with O
infectious D
mononucleosis D
and O
the O
effect O
of O
corticosteroid T
therapy T

Surgical T
treatment T
of O
uterine D
cervix D
insufficiency D
during O
the O
2d O
trimester O
of O
pregnancy O

Physiologic T
treatment T
of O
depressive D
reactions D
: O
a O
pilot O
study O

The O
use O
of O
quinidine T
sulphate T
for O
the O
treatment O
of O
atrial D
fibrillation D
in O
twelve O
horses O

Synergism O
in O
the O
chemotherapy T
of O
Eimeria D
infections D
of O
chicks O

Treatment O
of O
hydrocele D
and D
cysts D
of D
the D
epididymis D
with O
sclerosing T
injections T
of T
quinine T
and T
urea T
chlorhydrolactate T
in O
a O
30 O
per O
cent O
solution O

The O
single-place T
caisson T
in O
the O
treatment O
of O
decompression D
accidents D

Blood O
volume O
measurements O
in O
burn D
therapy T

Phenylbutazone T
and O
acute D
leukemia D
. O

The O
place O
of O
surgery T
in O
hypertrophic D
obstructive D
cardiomyopathy D
( D
idiopathic D
hypertrophic D
subaortic D
stenosis D
) D

The O
treatment O
of O
autoimmune D
hemolytic D
anemia D
with O
heparin T

Effects O
of O
clomiphene T
citrate T
on O
endometrial D
hyperplasia D
in O
the O
premenopausal O
female O

Prolonged O
use O
of O
methyldopa T
in O
severe D
hypertension D
in O
pregnancy O

The O
effects O
of O
social O
class O
and O
friends O
' O
expectations O
on O
oral O
polio D
vaccination T
participation O

Glutathione O
S-transferase O
activity O
in O
epithelial D
ovarian D
cancer D
: O
association O
with O
response O
to O
chemotherapy T
and O
disease O
outcome O

Interferon-alpha-2b T
in O
the O
management O
of O
patients O
with O
relapsed O
and/or O
refractory O
Hodgkin D
's D
disease D

< O
TO_SEE O
> O
Frontal D
dysfunction D
blocks O
the O
therapeutic O
effect O
of O
THA T
on O
attention O
in O
Alzheimer D
's D
disease D

Effects O
of O
clomipramine T
on O
plasma O
amino O
acids O
and O
serotonergic O
parameters O
in O
panic D
disorder D
and D
depression D
. O

Thalidomide T
for O
aphthous D
ulcers D
in O
HIV D
infection D

Aspirin T
therapy T
in O
diabetes D
mellitus D

Combined T
pancreas-/kidney T
transplantation T
as O
a O
standard O
procedure O
in O
therapy O
of O
kidney D
failure D
in D
type D
I D
diabetic D
patients D

Corticosteroid T
injections T
for O
sciatica D

Flutamide T
plus T
castration T
in O
patients O
with O
previously O
untreated O
prostate D
cancer D

The O
immediate O
effectiveness O
of O
electrical T
nerve T
stimulation T
and O
electrical T
muscle T
stimulation T
on O
myofascial D
trigger D
points D

In O
vitro O
radiation-induced O
apoptosis O
and O
tumour O
response O
to O
radiotherapy T
: O
a O
prospective O
study O
in O
patients O
with O
non-Hodgkin D
lymphomas D
treated O
by O
low-dose T
irradiation T

Drug T
therapy T
for O
coronary D
heart D
disease D
: O
the O
Sheffield O
table O

Percutaneous T
drainage T
of O
hydatid D
cysts D

Surgery T
for O
ectopia D
lentis D

< O
TO_SEE O
> O
Antiplatelet T
therapy T
to O
prevent O
stroke D
: O
risk O
of O
brain D
hemorrhage D
and O
efficacy O
in O
atrial T
fibrillation T

High-dose T
chemotherapy T
with T
autologous T
hematopoietic T
stem-cell T
support T
for O
breast D
cancer D
in O
North O
America O

Is O
concomitant T
radiotherapy T
and T
chemotherapy T
superior O
to O
optimal O
radiotherapy T
alone O
in O
anal D
cancer D
? O

Standard T
versus T
high-dose T
therapy T
in O
10+ O
breast D
cancer D

Anal O
continence O
after O
surgery T
for O
rectal D
prolapse D

Aspirin T
therapy T
for O
cardiovascular D
disease D

Dosing O
of O
amoxicillin/clavulanate T
for O
treatment O
of O
lower D
respiratory D
tract D
infection D

Pharmacoeconomic O
analysis O
of O
ampicillin-sulbactam T
versus O
cefoxitin T
in O
the O
treatment O
of O
intraabdominal D
infections D

New T
therapies T
for O
severe D
meningococcal D
disease D

Another O
potential O
use O
of O
troglitazone T
in O
noninsulin-dependent D
diabetes D
mellitus D

< O
TO_SEE O
> O
Jaw D
clenching D
following O
Gamma T
Knife T
treatment T
for O
trigeminal D
neuralgia D

The O
protective O
effect O
of O
condoms T
and O
nonoxynol-9 T
against O
HIV D
infection D

Evaluation O
of O
adjuvant T
psychological T
therapy T
in O
patients O
with O
testicular D
cancer D
: O
randomised O
controlled O
trial O

The O
effect O
of O
an O
endothelin-receptor T
antagonist T
, T
bosentan T
, O
on O
blood O
pressure O
in O
patients O
with O
essential D
hypertension D
. O

Guidelines O
for O
the O
use O
of O
antiretroviral T
agents T
in O
HIV D
-infected O
adults O
and O
adolescents O

Long-term O
therapy O
with O
long-acting T
octreotide T
( T
Sandostatin-LAR T
) T
for O
the O
management O
of O
acromegaly D

Are O
ABVD T
and O
MOPP/ABV T
truly O
equivalent O
for O
treating O
Hodgkin D
's D
disease D
at O
advanced O
stages O
? O

Paclitaxel T
for O
the O
treatment O
of O
lymphoma D

Montelukast T
, T
a T
leukotriene-receptor T
antagonist T
, T
for O
the O
treatment O
of O
mild D
asthma D
and D
exercise-induced D
bronchoconstriction D

Atypical O
antipsychotic T
agents T
in O
the O
treatment O
of O
Schizophrenia D
and D
other D
psychiatric D
disorders D

Percutaneous T
transluminal T
angioplasty T
in O
the O
treatment O
of O
renovascular D
hypertension D
: O
sequential O
prospective O
study O

Esophageal T
intubation T
for O
palliative O
treatment O
in O
advanced D
carcinoma D
of D
the D
esophagus D
and D
cardia D

Pathological O
staging O
and O
biochemical O
recurrence O
after O
neoadjuvant T
androgen T
deprivation T
therapy T
in O
combination O
with O
radical T
prostatectomy T
in O
clinically O
localized O
prostate D
cancer D

How O
often O
does O
surgery T
for O
peptic D
ulceration D
eradicate O
Helicobacter O
pylori O
? O
Systematic O
review O
of O
36 O
studies O

A O
comparison O
of O
noninvasive T
positive-pressure T
ventilation T
and O
conventional T
mechanical T
ventilation T
in O
patients O
with O
acute D
respiratory D
failure D

Long-term O
safety O
and O
effectiveness O
of O
iron-chelation T
therapy T
with T
deferiprone T
for O
thalassemia D
major D

Positron O
emission O
tomography O
in O
assessing O
response O
to O
neoadjuvant T
chemotherapy T
for O
non-small-cell D
lung D
cancer D

Reconstruction O
of O
thoracic O
wall O
defects O
after O
tumor D
resection T
using O
a O
polytetrafluoroethylene O
soft O
tissue O
( O
Gore-Tex O
) O
patch O

A O
comparison O
of O
rectal T
diazepam T
gel T
and O
placebo O
for O
acute D
repetitive D
seizures D

Effect O
of O
long-term O
salmeterol T
treatment T
on O
exercise-induced D
asthma D

Randomized O
trial O
of O
intensive T
cyclophosphamide T
, T
epirubicin T
, T
and T
fluorouracil T
chemotherapy T
compared O
with O
cyclophosphamide T
, T
methotrexate T
, T
and T
fluorouracil T
in O
premenopausal O
women O
with O
node-positive D
breast D
cancer D

Acute O
effect O
of O
lorazepam T
on O
respiratory O
muscles O
in O
patients O
with O
chronic D
obstructive D
pulmonary D
disease D

Low-molecular-weight T
heparins T
in O
the O
treatment O
of O
venous D
thromboembolism D

5-year O
outcome O
of O
surgical T
resection T
and O
watchful O
waiting O
for O
men O
with O
moderately O
symptomatic O
benign D
prostatic D
hyperplasia D
: O
a O
Department O
of O
Veterans O
Affairs O
cooperative O
study O

For O
how O
long O
should O
antipsychotic T
medication T
be O
continued O
after O
the O
first O
psychotic D
episode D
in D
schizophrenics D
? O

IDA-FLAG T
( T
idarubicin T
, T
fludarabine T
, T
cytarabine T
, T
G-CSF T
) T
, O
an O
effective O
remission-induction T
therapy T
for O
poor-prognosis D
AML D
of D
childhood D
prior O
to O
allogeneic O
or O
autologous O
bone O
marrow O
transplantation O
: O
experiences O
of O
a O
phase O
II O
trial O

< O
TO_SEE O
> O
Effects O
of O
anal T
invasive T
treatment T
and O
incontinence D
on O
mental O
health O
and O
psychosocial O
functioning O
of O
adolescents O
with O
Hirshsprung D
's D
disease D
and O
low O
anorectal D
anomalies D

Single O
or O
double O
lung T
transplantation T
for O
pulmonary D
hypertension D

Interferon T
beta T
treatment T
for O
multiple D
sclerosis D

Ten-year O
disease O
free O
survival O
after O
transperineal T
sonography-guided T
iodine-125 T
brachytherapy T
with O
or O
without O
45-Gray T
external T
beam T
irradiation T
in O
the O
treatment O
of O
patients O
with O
clinically O
localized O
, O
low O
to O
high O
Gleason D
grade D
prostate D
carcinoma D

Partial O
or O
near O
total O
pancreatectomy T
for O
persistent D
neonatal D
hyperinsulinaemic D
hypoglycaemia D
: O
the O
pathologist O
's O
role O

Radical T
prostatectomy T
for O
prostate D
cancer D
: O
the O
perineal O
approach O
increases O
the O
risk O
of O
surgically O
induced O
positive O
margins O
and O
capsular O
incisions O

Open T
capsulorrhaphy T
with T
suture T
anchors T
for O
recurrent D
anterior D
dislocation D
of D
the D
shoulder D

Intravenous T
immunoglobulin T
treatment T
in O
multiple D
sclerosis D

Randomised O
trial O
of O
irinotecan T
versus O
fluorouracil T
by O
continuous O
infusion O
after O
fluorouracil O
failure O
in O
patients O
with O
metastatic D
colorectal D
cancer D

The O
effectiveness O
of O
intraocular T
pressure T
reduction T
in O
the O
treatment O
of O
normal-tension D
glaucoma D

Perceived O
contraindications O
to O
thrombolytic T
treatment T
in O
acute D
myocardial D
infarction D

Lignocaine T
or O
bupivacaine T
for O
digital D
ring D
block D

Steroids T
in O
lateral D
epicondylitis D

Steroids T
in O
De D
Quervain D
's D
tenosynovitis D

Antibiotics T
after O
dog D
bite D

Immobilisation T
after O
first O
anterior O
shoulder D
dislocation D

Stereotactic T
radiosurgery T
for O
acoustic D
neuroma D
: O
a O
Canadian O
perspective O

Anticytokine T
therapy T
-- O
a O
new O
era O
in O
the O
treatment O
of O
rheumatoid D
arthritis D
? O

Control O
of O
the O
malignant D
hyperpyrexic D
syndrome D
in O
MHS O
swine O
by O
dantrolene T
sodium T

Hematopoietic T
stem-cell T
transplantation T
for O
the O
treatment O
of O
severe D
combined D
immunodeficiency D

Low-dose T
clozapine T
for O
the O
treatment O
of O
drug-induced D
psychosis D
in D
Parkinson D
's D
disease D

Comparing O
the O
efficacy O
and O
safety O
of O
fluoxetine T
and O
venlafaxine T
in O
outpatient D
depression D

Cost-effectiveness O
of O
interferon T
treatment T
for O
hepatitis D
C D

Hyperbaric T
oxygen T
therapy T
for O
children O
with O
cerebral D
palsy D

Peripheral T
retinal T
cryotherapy T
for O
postvitrectomy D
diabetic D
vitreous D
hemorrhage D
in O
phakic O
patients O

Hyperbaric T
or T
normobaric T
oxygen T
for O
acute D
carbon D
monoxide D
poisoning D
: O
a O
randomised O
controlled O
clinical O
trial O

Multicentre O
clinical O
evaluation O
of O
vigabatrin T
( T
Sabril T
) T
in O
mild D
to D
moderate D
partial D
epilepsies D

Matrix T
metalloproteinase T
inhibitors T
in O
the O
treatment O
of O
cancer D

High O
dose O
cyclophosphamide T
with O
carboplatin T
: O
a O
tolerable O
regimen O
suitable O
for O
dose O
intensification O
in O
children O
with O
solid D
tumors D

Microsurgical T
treatment T
of O
supratentorial D
cavernous D
malformations D

Microsurgical T
treatment T
of O
infratentorial D
malformations D

Stereotactic T
radiosurgery T
for O
management O
of O
deep D
brain D
cavernous D
malformations D

Interferon-antibodies T
and O
the O
breakthrough O
phenomenon O
during O
ribavirin/interferon-alpha T
combination T
therapy T
and O
interferon-alpha T
monotherapy T
of O
patients O
with O
chronic D
hepatitis D
C D

Treatment O
of O
Barrett D
esophagus D
with O
argon T
plasma T
coagulation T
with T
acid T
suppression T
-- O
a O
prospective O
study O

Meta-analysis O
of O
typhoid D
vaccine T
efficacy O
trials O
showed O
that O
whole O
cell O
vaccines O
are O
more O
effective O
than O
either O
the O
oral O
, O
attenuated O
vaccine O
or O
the O
Vi O
polysaccharide O
vaccine O

Experimental O
vaccination T
against O
Mycoplasma D
agalactiae D
using O
different O
inactivated O
vaccines O

A O
randomized O
, O
controlled O
study O
in O
adults O
of O
the O
immunogenicity O
of O
a O
novel O
hepatitis D
B D
vaccine T
containing O
MF59 O
adjuvant O

Immunogenicity O
of O
three O
Haemophilus D
influenzae D
type D
b D
protein O
conjugate O
vaccines T
in O
HIV O
seropositive O
adults O
and O
analysis O
of O
predictors O
of O
vaccine O
response O

Vaccination T
against O
Schistosoma D
mansoni D
infection D
using O
74 O
kDa O
Schistosoma O
protein O
antigen O

Phase O
1 O
safety O
and O
immune O
response O
studies O
of O
a O
DNA T
vaccine T
encoding O
hepatitis D
B D
surface O
antigen O
delivered O
by O
a O
gene O
delivery O
device O

Protection O
of O
swine O
from O
foot-and-mouth D
disease D
with O
one O
dose O
of O
an O
all-D T
retro T
peptide T

Intranasal T
immunization T
with O
Chlamydia D
trachomatis D
, D
serovar D
E D
, O
protects O
from O
a O
subsequent O
vaginal O
challenge O
with O
the O
homologous O
serovar O

Mutants O
of O
cholera O
toxin O
as O
an O
effective O
and O
safe O
adjuvant O
for O
nasal D
influenza D
vaccine T

Field O
evaluation O
of O
the O
clinical O
effectiveness O
of O
vaccines T
against O
pertussis D
, D
measles D
, D
rubella D
and D
mumps D
: O
comments O

Transmural T
drainage T
of O
pancreatic D
fluid D
collections D
without O
electrocautery O
using O
the O
Seldinger O
technique O

Echocardiography-guided T
ethanol T
septal T
reduction T
for O
hypertrophic D
obstructive D
cardiomyopathy D

Alterations O
of O
monocyte O
function O
in O
patients O
with O
growth D
hormone D
( D
GH D
) D
deficiency D
: O
effect O
of O
substitutive O
GH T
therapy T

Comparison O
of O
the O
effects O
of O
salmeterol T
and O
ipratropium T
bromide T
on O
exercise O
performance O
and O
breathlessness O
in O
patients O
with O
stable D
chronic D
obstructive D
pulmonary D
disease D
. O

< O
TO_SEE O
> O
Safety O
trial O
with O
the O
5HT1B/1D T
agonist T
avitriptan T
( O
BMS-180048 O
) O
in O
patients O
with O
migraine D
who O
have O
experienced O
pressure D
, D
tightness D
, D
and/or D
pain D
in O
the O
chest O
, O
neck O
, O
and/or O
throat O
following O
sumatriptan T

Double O
blind O
, O
cluster O
randomised O
trial O
of O
low O
dose O
supplementation O
with O
vitamin T
A T
or O
beta T
carotene T
on O
mortality D
related D
to D
pregnancy D
in O
Nepal O
. O

Medical T
treatments T
for O
balding D
in O
men O

Carbon D
monoxide D
poisoning D
treated O
with O
hyperbaric T
oxygen T
: O
metabolic O
acidosis O
as O
a O
predictor O
of O
treatment O
requirements O

Medication T
received O
by O
patients O
with O
depression D
following O
the O
acute O
episode O
: O
adequacy O
and O
relation O
to O
outcome O

< O
TO_SEE O
> O
Reduced D
bone D
density D
at O
completion O
of O
chemotherapy T
for O
a O
malignancy D

< O
TO_SEE O
> O
Surgical-site D
complications D
associated O
with O
a O
morphine T
nerve T
paste T
used O
for O
postoperative D
pain D
control D
after D
laminectomy D

Splenectomy T
during O
pregnancy O
: O
an O
option O
in O
the O
treatment O
of O
autoimmune D
thrombocytopenic D
purpura D

Melatonin T
treatment T
of O
sleep-wake D
cycle D
disorders D
in O
children O
and O
adolescents O

Randomized O
phase O
II O
study O
of O
the O
neurokinin T
1 T
receptor T
antagonist T
CJ-11 T
, T
974 T
in O
the O
control O
of O
cisplatin-induced D
emesis D

Cataract D
surgery T
and O
its O
effect O
on O
intraocular O
pressure O

The O
outcome O
of O
arthroscopic T
treatment T
of O
temporomandibular D
joint D
arthropathy D

Neostigmine T
for O
acute D
colonic D
pseudo-obstruction D

New O
vaccine T
targets O
childhood D
pneumonia D

A O
comparison O
of O
botulinum T
toxin T
and O
nitroglycerin T
ointment T
for O
chronic D
anal D
fissure D

< O
TO_SEE O
> O
The O
effect O
of O
bisoprolol T
on O
perioperative D
mortality D
and O
myocardial D
infarction D
in O
high-risk O
patients O
undergoing O
vascular T
surgery T

Surgical T
management T
of O
severe D
secondary D
peritonitis D

Early T
surgical T
treatment T
for O
supratentorial D
intracerebral D
hemorrhage D
: O
a O
randomized O
feasibility O
study O

Evaluation O
of O
clomipramine T
as O
an O
adjunct O
to O
behavioural T
therapy T
in O
the O
treatment O
of O
separation-related D
problems D
in O
dogs O

NICE O
to O
rule O
on O
influenza D
flu D
drug O
zanamivir T

< O
TO_SEE O
> O
Longitudinal D
melanonychia D
associated O
with O
hydroxyurea T
therapy T
in O
a O
patient O
with O
essential D
thrombocytosis D

Biologic O
markers O
as O
predictors O
of O
clinical O
outcome O
from O
systemic T
therapy T
for O
primary O
operable O
breast D
cancer D

Treatment O
of O
hypertension D
with O
ascorbic T
acid T

Postoperative D
peritonitis D
originating O
from O
the O
duodenum O
: O
operative O
management O
by O
intubation T
and T
continuous T
intraluminal T
irrigation T

Efficacy O
of O
open-bite D
treatment O
with O
the O
Thera-spoon T

< O
TO_SEE O
> O
Pompholyx D
( D
vesicular D
eczema D
) D
after O
i.v T
. T
immunoglobulin T
therapy T
for O
neurologic D
disease D

Mitomycin T
, T
ifosfamide T
, T
and T
cisplatin T
in O
unresectable D
non-small-cell D
lung D
cancer D
: O
effects O
on O
survival O
and O
quality O
of O
life O
. O

Hepatic O
arterial O
infusion O
of O
chemotherapy T
after O
resection T
of O
hepatic D
metastases D
from O
colorectal D
cancer D

Waiting O
for O
the O
definitive O
trial O
of O
hepatic T
arterial T
chemotherapy T
for O
colorectal D
cancer D

Phase O
III O
randomized O
study O
of O
cisplatin T
versus O
paclitaxel T
versus O
cisplatin T
and T
paclitaxel T
in O
patients O
with O
suboptimal O
stage O
III O
or O
IV O
ovarian D
cancer D
: O
a O
gynecologic O
oncology O
group O
study O

Evidence O
for O
double O
resistance O
to O
permethrin T
and T
malathion T
in O
head D
lice D

Urgent O
colonoscopy T
for O
the O
diagnosis O
and O
treatment O
of O
severe D
diverticular D
hemorrhage D

Treatment O
of O
Parkinson D
's D
disease D
should O
begin O
with O
a O
dopamine T
agonist T

< O
TO_SEE O
> O
Ulceration D
in O
an O
ileocolic D
anastomosis D
treated O
with O
ranitidin T

Low-molecular-weight T
heparin T
vs O
heparin T
in O
the O
treatment O
of O
patients O
with O
pulmonary D
embolism D

Radiotherapy T
in O
breast-conserving T
treatment T
for O
ductal D
carcinoma D
in O
situ O
: O
first O
results O
of O
the O
EORTC O
randomised O
phase O
III O
trial O
10853 O

Methadone T
maintenance T
vs O
180-day O
psychosocially O
enriched O
detoxification T
for O
treatment O
of O
opioid D
dependence D
: O
a O
randomized O
controlled O
trial O

Cryogen O
spray O
cooling O
during O
Nd T
: T
YAG T
laser T
treatment T
of O
hemangiomas D

Effects O
of O
tolcapone T
, T
a T
catechol-O-methyltransferase T
inhibitor T
, O
on O
motor O
symptoms O
and O
pharmacokinetics O
of O
levodopa T
in O
patients O
with O
Parkinson D
's D
disease D
. O

Gene T
therapy T
for O
cancer D

Therapeutic O
effects O
of O
LDL T
apheresis T
in O
the O
prevention O
of O
atherosclerosis D

Dry T
powdered T
formoterol T
, O
twice O
a O
day O
versus O
aerosolized T
salbutamol T
, O
four O
times O
a O
day O
, O
in O
patients O
with O
stable D
asthma D

Cell-based T
vaccination T
against O
melanoma D
-- O
background O
, O
preliminary O
results O
, O
and O
perspective O

Celecoxib T
for O
arthritis D

Poliomyelitis D
prevention O
: O
revised O
recommendations O
for O
use O
of O
inactivated O
and O
live O
oral O
poliovirus D
vaccines T

Mesh O
plug O
repair O
and O
groin D
hernia D
surgery T

Brimonidine T
tartrate T
0.2 O
% O
twice O
daily O
vs O
timolol T
0.5 O
% O
twice O
daily O
: O
1-year O
results O
in O
glaucoma D
patients O

Ticarcillin/clavulanate T
versus O
imipenem/cilistatin T
for O
the O
treatment O
of O
infections D
associated D
with D
gangrenous D
and D
perforated D
appendicitis D

Is O
zero O
dose O
oral O
polio D
vaccine T
effective O
in O
preterm O
babies O
? O

An O
economic O
analysis O
of O
different O
strategies O
of O
immunization T
against O
hepatitis D
A D
virus D
in O
developed O
countries O

Issues O
and O
challenges O
with O
antithrombotic T
therapy T
in O
diabetic O
patients O
with O
acute D
coronary D
syndromes D

Global O
risk O
assessment O
for O
lipid T
therapy T
to O
prevent O
coronary D
heart D
disease D

The O
role O
of O
fibric T
acid T
derivatives T
in O
the O
secondary O
prevention O
of O
coronary D
heart D
disease D

Epoetin T
: O
a O
pharmacoeconomic O
review O
of O
its O
use O
in O
chronic D
renal D
failure D
and O
its O
effects O
on O
quality O
of O
life O

Rationale O
for O
the O
use O
of O
antiplatelet T
drugs T
in O
patients O
with O
peripheral D
vascular D
disease D

The O
fluoroquinolones T
for O
urinary D
tract D
infections D
: O
a O
review O

Reduction O
of O
vasoreactivity D
and O
thrombogenicity D
with O
laser-thermal T
angioplasty T
: O
comparison O
with O
balloon T
angioplasty T

Effects O
of O
ultrasound T
energy T
on O
total D
peripheral D
artery D
occlusions D
: O
initial O
angiographic O
and O
angioscopic O
results O
. O

High-dose T
chemotherapy T
with T
autologous T
stem-cell T
support T
for O
epithelial D
ovarian D
cancer D

Pelvic T
floor T
stimulation T
in O
the O
treatment O
of O
adult D
urinary D
incontinence D

Chronic T
vagus T
nerve T
stimulation T
for O
treatment O
of O
seizures D

`` T
Tandem T
'' T
high-dose T
chemoradiotherapy T
with T
autologous T
stem-cell T
support T
in O
the O
treatment O
of O
newly O
diagnosed O
or O
responsive O
multiple D
myeloma D

Special O
report O
: O
comparative O
efficacy O
of O
different O
types O
of O
pneumatic T
compression T
pumps T
for O
the O
treatment O
of O
lymphedema D

Special O
report O
: O
pressure-reducing T
support T
surfaces T
in O
the O
prevention O
and O
treatment O
of O
pressure D
ulcers D
: O
group O
1 O
technologies O

Intravenous T
immune T
globulin T
for O
recurrent D
spontaneous D
abortion D

External T
counterpulsation T
for O
treatment O
of O
chronic D
stable D
angina D
pectoris D

Intra-articular T
hyaluronan T
injections T
for O
treatment O
of O
osteoarthritis D
of O
the O
knee O

Pneumococcal D
vaccine T
: O
a O
second O
look O

